BioSyent (RX.V) Stock Price
BioSyent Price
Revenue has compounded at 19.3% per year over the past 19 years to 43.05 M CAD. Earnings per share have grown at 18.6% per year over the last 19 years. BioSyent's net margin stands at 20.9%, down from 21.9% several years earlier. BioSyent currently offers a dividend yield of about 1.18%. The payout ratio is around 25% of earnings. The dividend has grown at 71.0% per year over the past 3 years. Analysts set a median price target of 16.83 CAD, implying 0.7% below the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.
BioSyent stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
BioSyent business model & stock analysis
Frequently asked questions about BioSyent
The business model of Biosyent Inc is focused on acquiring or in-licensing pharmaceutical and healthcare products. The company identifies niche markets with unmet medical needs and seeks regulatory approval to provide branded pharmaceuticals or health products that address those needs. Biosyent Inc aims to improve patient outcomes by offering innovative and effective treatment options in areas such as cardiovascular health, dermatology, neurology, and pediatrics. By partnering with established companies or acquiring the rights to specific products, Biosyent Inc brings affordable and quality medicines to market, providing patients with improved access to vital healthcare solutions.
Biosyent Inc is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Biosyent Inc in the market include pharmaceutical companies like Apotex Inc, Teva Pharmaceutical Industries Ltd, and Mylan N.V.
Biosyent Inc is a pharmaceutical company based in Canada. It was founded in 2004 and has since become a leader in the specialty pharmaceutical industry. The company focuses on acquiring or in-licensing niche pharmaceutical products, with a goal to provide reliable and effective therapeutic options to patients and healthcare professionals. Biosyent Inc has a successful track record of commercializing pharmaceutical products and has established a strong presence in the Canadian market. With a commitment to high-quality medications, Biosyent Inc continuously strives to meet the evolving healthcare needs of the population.
Biosyent Inc has achieved significant milestones since its inception. The company has successfully launched and commercialized multiple pharmaceutical and healthcare products in Canada. This includes obtaining regulatory approvals for important drugs, expanding their product portfolio, and establishing strategic partnerships with global pharmaceutical companies. Biosyent Inc has also demonstrated consistent revenue growth and increased market share, highlighting its strong performance in the industry. With their commitment to innovation and delivering high-quality products, Biosyent Inc continues to contribute to the advancement of healthcare and pharmaceuticals.
Biosyent Inc is primarily present in Canada and the United States.
Biosyent Inc is a pharmaceutical company that values innovation, sustainability, and customer-centricity. Their corporate philosophy revolves around providing high-quality, niche pharmaceutical products to meet the evolving healthcare needs of patients. With a focus on sourcing and licensing unique product opportunities, Biosyent Inc has built a strong reputation as a reliable partner within the healthcare industry. By utilizing their expertise in regulatory affairs and product commercialization, Biosyent Inc strives to improve patient outcomes while delivering value to their shareholders.
Analysts currently set an average price target of 16.83 CAD for the BioSyent stock (median: 16.83 CAD), implying -0.7 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the BioSyent stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect BioSyent to generate revenue of 73.20 M CAD and earnings per share of 1.05 CAD.
Converted at the current exchange rate, the BioSyent share trades at 10.82 EUR (16.95 CAD).
The BioSyent share (RX.V) is listed on 2 stock exchanges, including: Toronto (RX.V).
Biosyent Inc is a pharmaceutical company headquartered in Canada that focuses on the development, marketing, and distribution of innovative products. The company specializes in medications in the areas of dermatology, gastroenterology, urology, and pain management. The business strategy of Biosyent Inc is to bring new products to the market that are needed by the growing number of patients and healthcare providers. In addition, the company also produces generics, which it offers at lower costs than the originals. Biosyent Inc aims to improve the lives of patients through better healthcare solutions. The company is active in various regions and works with partners in Canada, the US, and Europe. Through targeted investments and marketing initiatives, Biosyent Inc has managed to expand its reach and diversify its offerings. The company collaborates closely with physicians, pharmacies, and customers to tailor its offerings to their needs. In the field of dermatology, the company offers preparations for acne, eczema, psoriasis, and other skin problems. In gastroenterology, Biosyent Inc has developed medications that can be used to treat gastrointestinal diseases such as inflammatory bowel disease, Crohn's disease, and ulcerative colitis. In urology, the company offers a solution for erectile dysfunction, and in pain management, it provides effective opioid antagonists in the form of nasal sprays and sublingual tablets. In addition to pharmaceutical products, Biosyent Inc also offers diagnostics and a solution for measuring urine flow. To further improve its products, the company also invests in researching new technologies and therapy forms. The company has a strong research and development department that works closely with the marketing and sales departments. Biosyent Inc strategically invests in the search for new active ingredients and solutions to continue offering its customers innovative products. Furthermore, the company works on optimizing its production processes and increasing its efficiency. The divisions of Biosyent Inc include: - Dermatology - Gastroenterology - Urology - Pain management Biosyent Inc. focuses on diversifying its offerings and producing innovative products that meet the needs of patients. Through the use of new technologies and procedures, the company aims to continue growing and strengthening its position in the market.
The expected revenue of BioSyent is 73.20 M CAD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of BioSyent is 11.81 M CAD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of BioSyent is currently 16.17. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BioSyent stock.
The price-to-sales ratio (P/S) of BioSyent is currently 2.61. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BioSyent stock.
The Eulerpool Quality Score for BioSyent is 8/10.
The ISIN of BioSyent is CA0906901081. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of BioSyent is A1J6DY. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of BioSyent is RX.V. The ticker symbol is used to trade BioSyent shares on the stock exchange.
BioSyent stock
BioSyent Peer Group
BioSyent Ticker
BioSyent FIGI
All fundamentals and in-depth analysis of BioSyent
Our stock analysis for BioSyent stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioSyent. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.